198 related articles for article (PubMed ID: 25623548)
21. Type 1 diabetes, metabolic syndrome and cardiovascular risk.
Chillarón JJ; Flores Le-Roux JA; Benaiges D; Pedro-Botet J
Metabolism; 2014 Feb; 63(2):181-7. PubMed ID: 24274980
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
J Endocrinol Invest; 2019 Oct; 42(10):1165-1169. PubMed ID: 30955180
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Protection with Anti-hyperglycemic Agents.
Deedwania P; Acharya T
Am J Cardiovasc Drugs; 2019 Jun; 19(3):249-257. PubMed ID: 30767126
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
25. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR.
Schernthaner G
Wien Med Wochenschr; 2010 Jan; 160(1-2):8-19. PubMed ID: 20229156
[TBL] [Abstract][Full Text] [Related]
26. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
[TBL] [Abstract][Full Text] [Related]
27. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus.
Kirkman MS; Mahmud H; Korytkowski MT
Endocrinol Metab Clin North Am; 2018 Mar; 47(1):81-96. PubMed ID: 29407058
[TBL] [Abstract][Full Text] [Related]
28. Divergent effects of various diabetes drugs on cardiovascular prognosis.
Bell DS; Patil HR; O'Keefe JH
Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
[TBL] [Abstract][Full Text] [Related]
29. Treatment of glycemic control in diabetes in the CVOT era.
Einhorn D
J Diabetes; 2020 Jan; 12(1):4. PubMed ID: 31746129
[No Abstract] [Full Text] [Related]
30. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
Dhar GC
Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265
[No Abstract] [Full Text] [Related]
31. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
Wareham NJ; Pfister R
Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
[TBL] [Abstract][Full Text] [Related]
32. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.
Giugliano D; Maiorino MI; Bellastella G; Chiodini P; Esposito K
J Am Heart Assoc; 2019 Jun; 8(12):e012356. PubMed ID: 31166153
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
36. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study.
Funamizu T; Iwata H; Nishida Y; Miyosawa K; Doi S; Chikata Y; Shitara J; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Miyauchi K; Daida H
Cardiovasc Diabetol; 2020 Feb; 19(1):21. PubMed ID: 32070335
[TBL] [Abstract][Full Text] [Related]
37. The impact of glucose-lowering therapy on cardiovascular outcomes.
Standl E; Müller M; Schnell O
Best Pract Res Clin Endocrinol Metab; 2009 Jun; 23(3):401-11. PubMed ID: 19520312
[TBL] [Abstract][Full Text] [Related]
38. Trials review: cardiovascular outcome with intensive glycemic control and implications for patients with type 2 diabetes.
Brown SH; Abdelhafiz AH
Postgrad Med; 2009 Sep; 121(5):31-41. PubMed ID: 19820272
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
40. Role of Purified Anthocyanins in Improving Cardiometabolic Risk Factors in Chinese Men and Women with Prediabetes or Early Untreated Diabetes-A Randomized Controlled Trial.
Yang L; Ling W; Yang Y; Chen Y; Tian Z; Du Z; Chen J; Xie Y; Liu Z; Yang L
Nutrients; 2017 Oct; 9(10):. PubMed ID: 28994705
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
